EXAONE Path 2.5: Pathology Foundation Model with Multi-Omics Alignment
About
Cancer progression arises from interactions across multiple biological layers, especially beyond morphological and across molecular layers that remain invisible to image-only models. To capture this broader biological landscape, we present EXAONE Path 2.5, a pathology foundation model that jointly models histologic, genomic, epigenetic and transcriptomic modalities, producing an integrated patient representation that reflects tumor biology more comprehensively. Our approach incorporates three key components: (1) multimodal SigLIP loss enabling all-pairwise contrastive learning across heterogeneous modalities, (2) a fragment-aware rotary positional encoding (F-RoPE) module that preserves spatial structure and tissue-fragment topology in WSI, and (3) domain-specialized internal foundation models for both WSI and RNA-seq to provide biologically grounded embeddings for robust multimodal alignment. We evaluate EXAONE Path 2.5 against six leading pathology foundation models across two complementary benchmarks: an internal real-world clinical dataset and the Patho-Bench benchmark covering 80 tasks. Our framework demonstrates high data and parameter efficiency, achieving on-par performance with state-of-the-art foundation models on Patho-Bench while exhibiting the highest adaptability in the internal clinical setting. These results highlight the value of biologically informed multimodal design and underscore the potential of integrated genotype-to-phenotype modeling for next-generation precision oncology.
Related benchmarks
| Task | Dataset | Result | Rank | |
|---|---|---|---|---|
| EGFR prediction | LUAD USA1 (test) | AUROC0.8555 | 8 | |
| KRAS prediction | LUAD USA2 (test) | AUROC0.7102 | 8 | |
| TMB10 prediction | LUAD USA1 (test) | AUROC69.36 | 8 | |
| TMB10 prediction | LUAD USA2 (test) | AUROC70.77 | 8 | |
| EGFR prediction | LUAD USA2 (test) | AUROC84.82 | 8 | |
| KRAS prediction | LUAD USA1 (test) | AUROC0.6022 | 8 | |
| MSI prediction | CRC KOR (test) | AUROC0.9791 | 8 | |
| Slide-level Pathology Prediction | Patho-Bench | BC Therapy ER Status0.658 | 7 |